Compare VATE & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VATE | CRDF |
|---|---|---|
| Founded | 1994 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.2M | 82.5M |
| IPO Year | 1996 | 2012 |
| Metric | VATE | CRDF |
|---|---|---|
| Price | $5.37 | $0.85 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $6.28 |
| AVG Volume (30 Days) | 54.4K | ★ 394.5K |
| Earning Date | 11-16-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 27.37 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,246,000,000.00 | $365,993.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $8.70 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 12.55 | ★ 49.61 |
| 52 Week Low | $3.75 | $0.76 |
| 52 Week High | $21.30 | $3.31 |
| Indicator | VATE | CRDF |
|---|---|---|
| Relative Strength Index (RSI) | 29.69 | 35.57 |
| Support Level | $5.35 | $0.76 |
| Resistance Level | $5.56 | $1.13 |
| Average True Range (ATR) | 0.36 | 0.08 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 4.02 | 23.79 |
Innovate Corp is a diversified holding company that has a portfolio of subsidiaries in a variety of operating segments. Its segments include Infrastructure, Life Sciences and Spectrum, and Other segment. Through its subsidiaries it provides fully integrated structural and steel construction services; supports healthcare and biotechnology product development; and operates Over-The-Air (OTA) broadcasting stations across the United States (U.S.) including Puerto Rico.
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.